Pentraxin 3 as a new biomarker of peritoneal injury in peritoneal dialysis patients

详细信息    查看全文

• 作者：Reo Kanda (1)
  Chieko Hamada (1)
  Kayo Kaneko (1)
  Takanori Nakano (1)
  Keiichi Wakabayashi (1)
  Hiroaki Io (1)
  Satoshi Horikoshi (1)
  Yasuhiko Tomino (1)
  
• 关键词：Pentraxin 3 (PTX3) ; Peritoneal dialysis ; Peritoneal injury ; Inflammation ; EPS
• 刊名：Journal of Artificial Organs
• 出版年：2013
• 出版时间：March 2013
• 年：2013
• 卷：16
• 期：1
• 页码：66-73
• 全文大小：659 KB
• 参考文献：1. Slingeneyer A, Canaud B, Mion C. Permanent loss of ultrafiltration capacity of the peritoneum in long-term peritoneal dialysis: an epidemiological study. Nephron. 1983;33:133-. CrossRef
  2. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant. 1996;11:498-06. CrossRef
  3. Dobbie JW. Morphology of the peritoneum in CAPD. Blood Purif. 1989;7:74-5. CrossRef
  4. Pollock CA, Ibels LS, Eckstein RP, Graham JC, Caterson RJ, Mahony JF, Sheil AG. Peritoneal morphology on maintenance dialysis. Am J Nephrol. 1989;9:198-04. CrossRef
  5. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, Kin M, Nakamoto M, Ohira S, Shoji T. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis. 2004;44:729-7.
  6. Yamagata K, Tomida C, Koyama A. Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1999;19:131-.
  7. Kawanishi H, Fujimori A, Tsuchida K, Takemoto Y, Tomo T, Minakuchi J, Yamamoto T, Kim M, Numata A, Choh S, Naito H, Peritoneal Effluent Study Group Japan. Markers in peritoneal effluent for withdrawal from peritoneal dialysis: multicenter prospective study in Japan. Adv Perit Dial. 2005;21:134-.
  8. Hirahara I, Inoue M, Okuda K, Ando Y, Muto S, Kusano E. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis—a multicentre study in Japan. Nephrol Dial Transplant. 2007;22:560-. CrossRef
  9. Yokoyama K, Yoshida H, Matsuo N, Maruyama Y, Kawamura Y, Yamamoto R, Hanaoka K, Ikeda M, Yamamoto H, Nakayama M, Kawaguchi Y, Hosoya T. Serum beta2microglobulin (beta2MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients. Clin Nephrol. 2008;69:121-.
  10. Numata M, Nakayama M, Hosoya T, Hoff CM, Holmes CJ, Schalling M, Nordfors L, Lindholm B. Possible pathologic involvement of receptor for advanced glycation end products (RAGE) for development of encapsulating peritoneal sclerosis in Japanese CAPD patients. Clin Nephrol. 2004;62:455-0.
  11. Nakamoto H. Encapsulating peritoneal sclerosis—a clinician’s approach to diagnosis and medical treatment. Perit Dial Int. 2005;25:S30-.
  12. Breviario F, d’Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, Saccone S, Marzella R, Predazzi V, Rocchi M. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem. 1992;267:22190-.
  13. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentraxin family of acute phase proteins. J Immunol. 1993;150:1804-2.
  14. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337-6. CrossRef
  15. Iwata Y, Yoshizaki A, Ogawa F, Komura K, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Takehara K, Sato S. Increased serum pentraxin3 in patients with systemic sclerosis. J Rheumatol. 2009;36:976-3. CrossRef
  16. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, Kurata T, Ota H, Mantovani A, Hamakubo T, Daida H, Kodama T. Establishment of high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007;27:161-. CrossRef
  17. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, Nielsen MP. Peritoneal equilibration test. Perit Dial Bull. 1987;7:138-7.
  18. He X, Han B, Bai X, Zhang Y, Cypel M, Mura M, Keshavjee S, Liu M. PTX3 as a potential biomarler of acute lung injury: supporting evidence from animal experimentation. Intensive Care Med. 2010;36:356-4. CrossRef
  19. Chenillot O, Henny J, Steinmetz J, Herbeth B, Wagner C, Siest G. High sensitivity C-reactive protein: biological variations and reference limits. Clin Chem Lab Med. 2000;38:1003-1. CrossRef
  20. Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta. 1993;221:91-03. CrossRef
  21. Nishizono I, Iida S, Suzuki N, Kawada H, Murakami H, Ashihara Y, Okada M. Rapid and sensitive chemiluminescent enzyme immuno-assay for measuring tumor markers. Clin Chem. 1991;37:1639-4.
  22. Honda K, Hamada C, Nakayama M, Miyazaki M, Sherif AM, Harada T, Hirano H, Peritoneal Biopsy Study Group of the Japanese Society for Peritoneal Dialysis. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol. 2008;3:720-. CrossRef
  23. Shimaoka T, Hamada C, Kaneko K, Io H, Sekiguchi Y, Aruga S, Inuma J, Inami Y, Hotta Y, Horikoshi S, Kumasaka T, Tomino Y. Quantitative evaluation and assessment of peritoneal morphologic changes in peritoneal dialysis patients. Nephrol Dial Transplant. 2010;25:3379-5. CrossRef
  
• 作者单位：Reo Kanda (1)
  Chieko Hamada (1)
  Kayo Kaneko (1)
  Takanori Nakano (1)
  Keiichi Wakabayashi (1)
  Hiroaki Io (1)
  Satoshi Horikoshi (1)
  Yasuhiko Tomino (1)
  
  1. Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, 2-1-1 Hongo Bunkyo-ku, Tokyo, 113-8421, Japan
  
• ISSN：1619-0904

文摘

It is well known that bioincompatible peritoneal dialysate plays a central role in the development of peritoneal fibrosis. Peritoneal inflammation continues even after the cessation of peritoneal dialysate stimulation. It is important to establish the definition of persistent inflammation in the peritoneal cavity at the cessation of peritoneal dialysis (PD). The objective of the present study was to determine whether pentraxin 3 (PTX3) in peritoneal effluent (PE) may be a new biomarker in PD patients. Serum, PE, and peritoneal specimens were obtained from 50 patients with end-stage kidney disease at Juntendo University Hospital. Samples of 19 patients were obtained at the initiation of PD and those of 31 patients at the cessation of PD. PTX3, high-sensitivity CRP, and MMP-2 and IL-6 were analyzed. An immunohistological examination using an anti-PTX3 antibody was performed. Expressions of PTX3 were observed in endothelial cells, fibroblasts, and mesothelial cells in the peritoneum. The PTX3 level in PE at the cessation of PD was significantly higher than that at the initiation of PD. Effluent PTX3 levels in patients with a history of peritonitis or a PD duration of more than 8?years were significantly higher than those in patients without peritonitis or patients with a PD duration of <8?years. The PTX3 level was significantly correlated with MMP-2 and IL-6 levels in PE, as well as the thickness of the submesothelial compact zone and the vasculopathy. It appears that PTX3 may be a new biomarker of peritoneal inflammation and progressive fibrosis.